坦帕诺治疗血液透析型慢性肾病相关的高磷血症  

Tenapanor for the Treatment of Patients Receiving Hemodialysis with Hyperphosphatemia Associated with Chronic Kidney Disease

作　　者：席敦香 XI Dun-xiang(Department of Blood Purification,the People's Hospital of Linqu,Linqu 262600,China)

机构地区：[1]临朐县人民医院血液净化科,山东临朐262600

出　　处：《药物生物技术》2020年第6期594-596,共3页Pharmaceutical Biotechnology

摘　　要：高磷血症是慢性肾病的常见并发症,严重危害人体健康,有效控制高磷血症可改善患者的预后。坦帕诺是治疗便秘型肠易激综合征的钠氢交换蛋白3抑制剂,被最近的临床试验证实能有效缓解血液透析型高磷血症。该药不同于传统的治疗策略,提供了一种全新疗法,展示了良好的临床应用前景。本文概述它的作用机制、药动学、药物相互作用、合理用药、临床疗效和不良反应,旨在为医生和患者提供有益参考。Hyperphosphatemia is a common complication of chronic kidney disease which severely damages the human health.The prognosis of patients with nephropath is enhanced by effective control of hyperphosphatemia.Tenapanor,as a sodium/hydrogen exchanger 3 inhibitors in the treatment of irritable bowel syndrome with constipation,was clinically demonstrated to have therapeutic effect in remission of hemodialysis-associated hyperphosphatemia.Unlike the traditional therapy,it represents a novel treatment pattern,showing the good prospect in the clinical application.The article outlined that its action mechanism,pharmacokinetics,proper administration,clinical efficacy and adverse events,afford the beneficial guidelines for the doctors and the patients.

关 键 词：坦帕诺 血液透析 高磷血症 肾病 钠氢交换蛋白 抑制剂 

分 类 号：R692[医药卫生—泌尿科学]